Recruiting Ankylosing Spondylitis Studies in Murrieta
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in...
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared t...
[18F]PI-2620 Phase 3 Histopathological Study
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Al...
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the ...
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participan...
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to s...
About Ankylosing Spondylitis Clinical Trials in Murrieta
Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.
There are currently 6 ankylosing spondylitis clinical trials recruiting participants in Murrieta, CALIFORNIA. These studies are seeking a combined 872 participants. Research is being sponsored by Takeda, Abivax S.A., Life Molecular Imaging Ltd and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ankylosing Spondylitis Clinical Trials in Murrieta — FAQ
Are there ankylosing spondylitis clinical trials in Murrieta?
Yes, there are 6 ankylosing spondylitis clinical trials currently recruiting in Murrieta, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Murrieta?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Murrieta research site will contact you about next steps.
Are clinical trials in Murrieta free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Murrieta studies also compensate for your time and travel.
What ankylosing spondylitis treatments are being tested?
The 6 active trials in Murrieta are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.
Data updated March 2, 2026 from ClinicalTrials.gov